Evidence map›Paper›PMID 39699213›Full record

ArticleAntimicrobial agents and chemotherapy2025

Pooja Ghatbale, Govind Prasad Sah, Sage Dunham, Ethan Khong, Alisha Blanc, Alisha Monsibais, Andrew Garcia, Robert T Schooley, Ana G Cobián Güemes, Katrine Whiteson and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Impact of carbapenem-resistantMicrobiology spectrum · 2026
    Article
  3. Antibiotics (Basel, Switzerland) · 2025
    Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Pooja Ghatbale *Department of Pathology, University of California, San Diego, California, USA.
Govind Prasad Sah *Department of Pathology, University of California, San Diego, California, USA.ORCID 0000-0003-2697-7656
Sage DunhamDepartment of Molecular Biology and Biochemistry, University of California, Irvine, California, USA.ORCID 0000-0002-6338-5038
Ethan KhongDepartment of Pathology, University of California, San Diego, California, USA.
Alisha BlancDepartment of Pathology, University of California, San Diego, California, USA.
Alisha MonsibaisDepartment of Molecular Biology and Biochemistry, University of California, Irvine, California, USA.ORCID 0000-0001-6874-9171
Andrew GarciaDepartment of Pathology, University of California, San Diego, California, USA.
Robert T SchooleyDepartment of Medicine, University of California, San Diego, California, USA.
Ana G Cobián GüemesDepartment of Pathology, University of California, San Diego, California, USA.ORCID 0000-0002-0755-5864
Katrine WhitesonDepartment of Molecular Biology and Biochemistry, University of California, Irvine, California, USA.ORCID 0000-0002-5423-6014
David T PrideDepartment of Pathology, University of California, San Diego, California, USA.ORCID 0000-0001-8161-6015

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bacteriophages are an increasingly attractive option for the treatment of antibiotic-resistant infections, but their efficacy is difficult to discern due to the confounding effects of antibiotics. Phages are generally delivered in conjunction with antibiotics, and thus, when patients improve, it is unclear whether the phages, antibiotics, or both are responsible. This question is particularly relevant for enterococcus infections, as limited data suggest phages might restore antibiotic efficacy against resistant strains. Enterococci can develop high-level resistance to vancomycin, a primary treatment. We assessed clinical and laboratory isolates of

Indexed as

Anti-Bacterial AgentsBacteriophagesEnterococcus faecalisEnterococcus faeciumAmpicillinDrug Resistance, Multiple, BacterialGram-Positive Bacterial InfectionsHumansLinezolidMicrobial Sensitivity TestsVancomycinAmpicillinAnti-Bacterial AgentsLinezolidVancomycinantibioticsbacteriophagescooperativityresensitizationsynergy

Identifiers

PMID39699213
PMCPMC11823633

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.